Changes in CETA bill seek to streamline litigation in pharma industry

In the wake of the Comprehensive Economic and Trade Agreement signing, the federal government has introduced an amendment bill into Parliament that will provide for a two-year drug patent term extension and drug litigation proceedings will be turned into full actions.
Bereskin & Parr LLP lawyer Noel Courage says new rules will give pharmaceutical companies two more years of patent protection.Bill C-30, An Act to implement the Comprehensive Economic and Trade Agreement between Canada and the European Union and its Member States, was introduced on Oct. 31. It will implement portions of CETA and provide authority to replace the current …
Go to Source